Abivax Concludes Successful Public Offering for $747.5 Million

Author: Evelyn Baker Updated: 07-28-2025 04:33 PM

Abivax Celebrates Successful Financing with $747.5 Million Offering

Abivax, a clinical-stage biotechnology firm, is excited to announce the closing of its recently completed public offering, securing approximately $747.5 million. This funding comes at a crucial time as the company focuses on developing innovative therapies aimed at regulating the immune response in patients facing chronic inflammatory diseases.

Financial Details of the Offering

The public offering comprised 11,679,400 American Depositary Shares (ADSs), with each representing an ordinary share of Abivax. Notably, this offering saw the full exercise of the underwriters' option to purchase additional ADSs, further enhancing the proceeds. The gross amount raised, before the deduction of offering expenses and underwriting commissions, is estimated at €637.5 million, or around $747.5 million. The net proceeds expected amount to roughly $700.3 million, post-deductions.

Impact on Operations and Future Plans

Abivax's management believes this significant influx of capital will enable the company to sustain its operations and clinical development plans well into the fourth quarter of 2027. More specifically, the anticipated timeline allows Abivax to progress through the next twelve months, following the projected New Drug Application (NDA) submission for their promising treatment of Ulcerative Colitis, assuming favorable outcomes from ongoing clinical trials.

Strategic Support and Underwriters

Leading the offering were prominent firms including Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, which acted as joint bookrunning managers. LifeSci Capital took the role of lead manager, with additional support from BTIG and Van Lanschot Kempen as co-managers. Their combined expertise is expected to facilitate a successful transition into the expected phases following this capital raise.

Company's Vision and Commitment

Based in France and the United States, Abivax is committed to harnessing natural bodily processes to develop therapeutic strategies that alleviate chronic inflammatory diseases. Their lead candidate, obefazimod (ABX464), is currently in Phase 3 trials, specifically targeting moderately to severely active ulcerative colitis. The ongoing research and development efforts remain pivotal in Abivax's mission to produce effective treatments that enhance patients' quality of life.

Contact Information for Further Inquiries

For investors looking for more information about the offering or the company's future endeavors, Abivax has made a point to retain open lines of communication. Abivax Investor Relations can be reached through Patrick Malloy at +1 847 987 4878 or via email at patrick.malloy@abivax.com.

Frequently Asked Questions

What was the total amount raised in the public offering?

Abivax successfully raised approximately $747.5 million in its latest public offering.

How many American Depositary Shares were offered?

The offering included a total of 11,679,400 American Depositary Shares.

What are the intended uses for the funds raised?

The funds will primarily support ongoing operations and clinical developments as Abivax approaches its NDA submission.

Which firms managed the public offering?

Leerink Partners, Piper Sandler & Co., and Guggenheim Securities acted as the main managers for the offering.

What is Abivax's lead drug candidate?

Abivax's lead candidate is obefazimod (ABX464), aimed at treating ulcerative colitis and currently in Phase 3 trials.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.